Price T Rowe Associates Inc Celldex Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

$883 Billion
Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,817,820 shares of CLDX stock, worth $96.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,817,820

Previous 3,410,499 11.94%

Holding current value

$96.2 Million

Previous $61.9 Million 25.51%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$15.13 - $21.65 $6.16 Million - $8.82 Million	407,321 Added 11.94%	3,817,820 $77.7 Million
Q1 2025 May 14, 2025	SELL	$18.15 - $27.6 $2.66 Million - $4.05 Million	-146,637 Reduced 4.12%	3,410,499 $61.9 Million
Q4 2024 Feb 14, 2025	BUY	$23.31 - $32.4 $15.8 Million - $21.9 Million	676,771 Added 23.5%	3,557,136 $89.9 Million
Q3 2024 Nov 14, 2024	SELL	$32.06 - $44.56 $9.36 Million - $13 Million	-292,034 Reduced 9.21%	2,880,365 $97.9 Million
Q2 2024 Aug 14, 2024	BUY	$32.76 - $42.56 $2.79 Million - $3.63 Million	85,191 Added 2.76%	3,172,399 $117 Million
Q1 2024 May 15, 2024	BUY	$35.22 - $51.88 $93.9 Million - $138 Million	2,664,915 Added 631.06%	3,087,208 $130 Million
Q4 2023 Feb 14, 2024	SELL	$22.61 - $40.65 $1.03 Million - $1.86 Million	-45,762 Reduced 9.78%	422,293 $16.7 Million
Q3 2023 Nov 14, 2023	SELL	$25.45 - $37.46 $267,708 - $394,041	-10,519 Reduced 2.2%	468,055 $12.9 Million
Q2 2023 Aug 14, 2023	SELL	$30.29 - $38.28 $7.12 Million - $9 Million	-234,988 Reduced 32.93%	478,574 $16.2 Million
Q1 2023 May 15, 2023	SELL	$34.78 - $47.43 $4.15 Million - $5.67 Million	-119,447 Reduced 14.34%	713,562 $25.7 Million
Q4 2022 Feb 14, 2023	BUY	$27.78 - $45.38 $2.42 Million - $3.95 Million	87,001 Added 11.66%	833,009 $37.1 Million
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $4.83 Million - $7.99 Million	212,606 Added 39.86%	746,008 $21 Million
Q2 2022 Aug 15, 2022	SELL	$20.5 - $37.33 $10.7 Million - $19.4 Million	-520,923 Reduced 49.41%	533,402 $14.4 Million
Q1 2022 May 16, 2022	BUY	$27.64 - $39.32 $3.83 Million - $5.45 Million	138,717 Added 15.15%	1,054,325 $35.9 Million
Q4 2021 Feb 14, 2022	BUY	$35.68 - $56.27 $1.33 Million - $2.09 Million	37,199 Added 4.23%	915,608 $35.4 Million
Q3 2021 Nov 15, 2021	BUY	$28.95 - $55.99 $14.2 Million - $27.4 Million	489,361 Added 125.78%	878,409 $47.4 Million
Q2 2021 Aug 16, 2021	BUY	$20.71 - $35.37 $1.18 Million - $2.01 Million	56,818 Added 17.1%	389,048 $13 Million
Q1 2021 May 17, 2021	BUY	$16.19 - $29.91 $634,032 - $1.17 Million	39,162 Added 13.36%	332,230 $6.84 Million
Q4 2020 Feb 16, 2021	BUY	$14.99 - $22.75 $4.39 Million - $6.67 Million	293,068 New	293,068 $5.14 Million

Others Institutions Holding CLDX

# of Institutions

198

Shares Held

68.2M

Call Options Held

219K

Put Options Held

238K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.18B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Celldex Therapeutics, Inc. Transaction History